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Since the ﬁrst observations on the existence of “neurosteroids” in the 1980s, our under-
standing of the importance of these endogenous steroids in the control of the central
and peripheral nervous system (PNS) has increased progressively. Although most of the
observations were made in neuronal cells, equally important are the effects that neuros-
teroids exert on glial cells. Among the different classes of neurosteroids acting on glial
cells, the progesterone 5α-3α metabolite, allopregnanolone, displays a particular mecha-
nism of action involving primarily the modulation of classic GABA receptors. In this review,
we focus our attention on allopregnanolone because its effects on the physiology of glial
cells of the central and PNS are intriguing and could potentially lead to the development of
new strategies for neuroprotection and/or regeneration of injured nervous tissues.
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INTRODUCTION
The ﬁrst observations on the existence of “nervous steroids”
appeared in the early 1980s, introducing the novel concept that
some hormonal steroids may be synthesized de novo in the ner-
vous system. Baulieu (1997) coined the term “neurosteroids” in
order to deﬁne such molecules. Over the years, the importance
of such endogenous steroids in the control of both the central
nervous system (CNS) and peripheral nervous system (PNS) has
become increasingly apparent. However, most of the observations
were made through investigations into their role in neuronal cells.
Equally important are the putative effects that neurosteroids may
directly exert on glial cells by regulating their physiological func-
tions, or even indirectly through the complex interactions with
neuronal cells.
It is now generally believed that central (i.e., astrocytes, oligo-
dendrocytes) and peripheral glial cells (i.e., Schwann cells, SC)
are fundamental for the regulation of neuronal activity. They
Abbreviations: 3α-HSD, 3α-hydroxysteroid-dehydrogenase; 3βHSD, 3β-
hydroxysteroid-dehydrogenase; 5HT3, 5-hydroxytryptamine type 3; 17αHSD,
17α-hydroxysteroid-dehydrogenase; ALLO, allopregnanolone; AR, androgen
receptor; bFGF, basic ﬁbroblast growth factor; CMT1A, Charcot Marie Tooth type
1A; CNPase, 2′-3′-cyclic nucleotide-3-phospodiesterase; CREB, cAMP response
element-binding protein; DHP, dehydroprogesterone; EAAC1, excitatory amino
acid transporter 1; ER, estrogen receptor; GABA, γ-aminobutyric acid; GABA-A,
GABA type A receptor; GABA-B, GABA type B receptor; GAD67, glutamic acid
decarboxylase of 67 kDa; GFAP, glial ﬁbrillary acid protein; IGF-I, insulin-like
growth factor-I; LHRH, luteinizing-hormone-releasing hormone; MAG, myelin
associated glycoprotein; MBP, myelin basic protein; mER, membrane estrogen
receptor; mPR, membrane progesterone receptor; NMDA, N -Methyl-d-aspartate;
P450SCC, P450 cholesterol side-chain cleavage enzyme; P, progesterone; P0, myelin
protein zero; PK-A, protein kinase A; PK-C, protein kinase C; PMP22, peripheral
myelin protein of 22 kDa; PNS, peripheral nervous system; PR, progesterone
receptor; PSA-NCAM+, polysialylated-neural cell adhesion molecule positive cells;
SC, Schwann cells; 5α-R, 5α-reductase; T, testosterone; TGFα, transforming growth
factor α; TGFβ1, transforming growth factor β1; TGFβ2, transforming growth
factor β2; TNFα, tumor necrosis factor α.
support neuron metabolism and survival, they can uptake and
produce neurotransmitters and they are also able to synthesize
neurosteroids (Celotti et al., 1992; Melcangi et al., 2001b). Glial
cells, indeed, possess all the enzymatic pathways and the synthetic
machinery required to produce steroids (that is the P450 choles-
terol side-chain cleavage enzyme, P450SCC; 17α-hydroxysteroid-
dehydrogenase, 17α-HSD; 3β-hydroxysteroid-dehydrogenase, 3β-
HSD and other enzymes), or to convert them into neuroac-
tive metabolites (Mellon et al., 2001). In particular, the enzy-
matic complex formed by the 5α-reductase (5α-R) and the 3α-
hydroxysteroid-dehydrogenase (3α-HSD) enzymes has been char-
acterized in several areas of the human brain (Steckelbroeck et al.,
2001) and in the PNS (Melcangi et al., 1990b, 1992, 1999b; Celotti
et al., 1992). The combined action of these two enzymes catalyzes
the conversion of some native steroids, such as progesterone (P),
into their more active 5α-3α-reduced metabolites, that is into
“neurosteroids.” This enzymatic complex is extremely versatile
since every steroid possessing the δ4-3keto conﬁguration could
potentially undergo the 5α-reduction and subsequently be sub-
jected to 3α-hydroxylation (Celotti et al., 1992; Melcangi et al.,
1999b, 2000c). By analyzing the ability of puriﬁed primary cell
cultures of neurons, astrocytes (type 1 and type 2 astrocytes) or
oligodendrocytes to metabolize testosterone (T; Melcangi et al.,
1990a, 1993, 1994), it has been demonstrated that neurons pos-
sess signiﬁcantly higher amounts of 5α-R activity compared to
astrocytes and oligodendrocytes (Melcangi et al., 1993, 1994).
Interestingly, the simultaneous presence of neurons and type 1
astrocyte cultures stimulates the 5α-R activity (Melcangi et al.,
2001c), indicating a possible interaction of these cells in themetab-
olism of neurosteroids. It is also reasonable to speculate that the
metabolism of neurosteroids may be relevant for differentiation
of glia. Gago et al. (2001) showed that the formation of the 5α-
reduced metabolite of P, dehydroprogesterone (DHP), is ﬁvefold
higher in fully differentiated oligodendrocytes compared to oligo-
dendrocyte progenitor cells. This suggests that the acquisition
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of the neurosteroids biosynthetic capacity is a marker of glial
differentiation. In addition, the reaction catalyzed by 3α-HSD
involves the replacement of a carbonyl with a hydroxyl group, lead-
ing to the formation of metabolites that are potent modulators
of non-classical steroid receptors (see below). Some biochemi-
cal studies demonstrated that 3α-HSD is distributed in various
regions of the rodent brain (Khanna et al., 1995; Mellon et al.,
2001; Agis-Balboa et al., 2007), where it is mainly localized in type
1 astrocytes (Melcangi et al., 1993, 1994) and in oligodendrocytes
(Melcangi et al., 1994). The 5α-R-3α-HSDactivity is also present in
the SC of the PNS (Melcangi et al., 1990b, 1998, 1999b;Yokoi et al.,
1998). Therefore, the ability to synthesize or metabolize particular
arrays of steroids seems to be region-speciﬁc in the different CNS
areas and conﬁned to glial cells (Mellon et al., 2001). In line with
this hypothesis, the 5α-R activity in the myelin forming cells of
the CNS and PNS (that is oligodendrocytes and SC, respectively)
appeared different, being about four times higher in SC compared
to oligodendrocytes (Melcangi et al., 1998). Thus, the presence of
the 5α-R-3α-HSD enzymatic complex in oligodendrocytes and SC
suggests that the locally formed neurosteroids might play a crucial
role in the process of myelination (Melcangi et al., 1988, 2001c;
Martini et al., 2003).
The neurosteroid 5α-pregnan-3α-ol-20-one, also named
tetrahydroprogesterone or allopregnanolone (ALLO) is the most
important hormonal steroid that was originally shown to act as
a neurosteroid. It is synthesized through the action of the 5αR-
3α-HSD, which converts P into DHP and subsequently, via a
bidirectional reaction, into ALLO (see Figure 1, in SC). Interest-
ingly,ALLO is able tomodulate several neuronal cell functions. For
instance, it is proven to be a neurogenic molecule, inducing a dose
dependent signiﬁcant increase in proliferation of rat neural prog-
enitor cells and of human neural stem cells (Wang et al., 2005), or
affecting cerebellar neurogenesis (Keller et al., 2004). Besides these
studies revealing ALLO’s actions on the neuronal compartment,
several observations have suggested important roles for ALLO on
glial cells. In this review we attempt to summarize the intrigu-
ing modulations and the therapeutic potential of the neurosteroid
ALLO on the glial cells of the CNS and PNS.
MECHANISM OF ACTION OF NEUROSTEROIDS
Neurosteroids exert complex effects in the nervous system through
“classic” and “non-classic” actions. The “classic” genomic action
consists of the modulation of their target cells by regulating gene
transcription after binding to nuclear receptors (Slater et al., 1994).
By contrast, the rapid “non-classic” action involves the modula-
tion of neurotransmitter receptors, that is γ-aminobutyric acid
(GABA), N -Methyl-d-aspartate (NMDA), 5-hydroxytryptamine
type 3 (5HT3) and σ-receptors (Lambert et al., 1996; Rupprecht
et al., 2001; Monnet and Maurice, 2006; Sedlacek et al., 2008)
and the activation of novel putative membrane receptors for
steroids (Hammes and Levin, 2007; Dressing et al., 2011; Levin,
2011). Some of these receptors have been found in glial cells (see
Tables 1–3).
Allopregnanolone is a potent modulator of the GABA type
A (GABA-A) receptor (Majewska et al., 1986; Majewska, 1992;
Lambert et al., 1995). In fact, the most important and well-
characterized “non-classic,” non-genomic action of neurosteroids
is represented by the ALLO’s activation of GABA-A receptor
functions (Majewska et al., 1986; Rupprecht and Holsboer, 1999;
Lambert et al., 2003). Interestingly, ALLO’s mechanism of action
on GABA-A receptor is concentration dependent. Indeed, in
the low nanomolar aqueous concentration ALLO acts alloster-
ically, enhancing the action of the natural ligand GABA, while
at higher concentration (micromolar range) ALLO directly gates
the GABA-A receptor channel complex (Callachan et al., 1987;
Puia et al., 1990). However, it has been shown that neurosteroids
may directly gate GABA-A receptors also at lower concentra-
tion, around 100 nM, but the kinetic of this receptor activation
is relatively slow (Shu et al., 2004).
The GABA-A receptor is a member of the ligand-gated ion
channel family, permeable to chloride ions and composed of
ﬁve subunits drawn from a repertoire of 19 isoforms (that is
α1–6, β1–3, γ1–3, δ, ε, π, θ, ρ1–3; Whiting et al., 1995, 1997;
Lambert et al., 2003). The GABA-A receptor is blocked by bicu-
culline and picrotoxin, but channel opening is enhanced by
benzodiazepines, barbiturates, anesthetics and also neurosteroids
(Park-Chung et al., 1999; Belelli and Lambert, 2005). Interest-
ingly, the GABA-A receptor modulation exerted by neurosteroids
is enantioselective and is partially dependent upon the receptor
subunit composition. For this reason several studies were aimed at
elucidating the putative neurosteroids external binding sites (Lam-
bert et al., 2003). Although no special requirement concerning the
nature of the α and β subunits seems to be essential to confer sen-
sitivity to neurosteroids (Belelli et al., 2002), a receptor composed
of one α (α2–5) assembled with β3 and γ2S subunits gives con-
sistent potentiation of ALLO-mediated GABA-activated currents
(Hosie et al., 2009). Moreover, γ2 subunits confer more sensitiv-
ity than γ1 or γ3 (Belelli et al., 2002), while δ subunit potentiates
the action of the 5α-3α-reduced neurosteroids (Mihalek et al.,
1999; Belelli et al., 2002). The extrasynaptic GABA-A receptor
incorporating the δ subunit, indeed, is an important and highly
sensitive target of neurosteroids (Lambert et al., 2009), implicating
the δ-containing receptors as the preferred target for the action of
neurosteroids.Nevertheless, the δ subunit seems toprimarily inﬂu-
ence the transduction of neurosteroid signals rather than engage
directly in binding (Hosie et al., 2009).
Neurosteroidsmight also indirectly target the receptor function
by regulating the transcription of some GABA-A receptor sub-
units, thus altering theGABA-A inhibitory activity for a prolonged
time (Maguire andMody,2009).Neurosteroidsmight also interact
with protein kinase or phosphatases,which in turn act onGABA-A
subunits altering the entire receptor function (Belelli and Lambert,
2005). Likewise, phosphorylation of GABA-A receptors by pro-
tein kinase C (PK-C) inﬂuences the sensitivity to neurosteroids
(Brussaard and Koksma, 2003; Vergnano et al., 2007).
Beside the external binding sites of GABA-A receptor,
some recent evidence supports a novel hypothesis suggesting
that neurosteroids require a membranous route of access to
transmembrane-domain binding sites within GABA-A receptor
(Shu et al., 2004; Akk et al., 2005; Hosie et al., 2006; Chisari et al.,
2009). Once neurosteroids reach the site of action they may dif-
fuse through the plasma membrane to directly bind the GABA-A
receptor, rather than interacting with external binding sites of
the receptor. This is a low-afﬁnity receptor interaction that might
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depend on the lipid composition of the cell membrane. Neuros-
teroids may be also retained in the intracellular compartment and
then re-supply the plasma membrane with ligands able to mod-
ulate the GABA-A receptor at later times, so that the rate of this
transport can alter the kinetics of neurosteroids actions (Akk et al.,
2005).
The proposed mechanisms of ALLO’s action, however, may
be in principle complementary to the classic genomic effects.
Indeed, an indirect action of ALLO involving the classic prog-
esterone receptor (PR) should not be totally excluded. In such a
scenario, ALLO’s action closely depends on its retro-conversion to
DHP, operated by enzyme 3α-HSD (Martini et al., 2003), which
may then stimulate the PR generating a classic genomic effect. In
comparison to ALLO’s rapid interaction with GABA-A receptors,
the PR-mediated mechanism shows slower kinetics and lasts for a
longer time.
Finally, concerning the ALLO interaction with the GABAer-
gic system, its putative ability to interact with the metabotropic
GABA-B receptor should not be totally excluded, although
the evidence that such an interaction effectively occurs is not
clearly provided. GABA-B receptor is a distinct, baclofen-sensitive,
metabotropic receptor that is a member of the seven transmem-
braneG-protein-coupled receptor superfamily. GABA-B receptors
may inﬂuence the activity of adenylate cyclase and/or modu-
late calcium and potassium channels activity (Bowery and Enna,
2000). In this regard, we have recently demonstrated in vitro
a cross-correlation between the GABA-A and B receptors in
SC (Magnaghi, 2007), and some of these effects are discussed
below.
ALLO’s EFFECT ON ASTROCYTE
Neurosteroids are known to control the proliferation, cell shape,
and gene expression of CNS astroglia (Garcia-Segura et al., 1996,
1999; Jordan, 1999; Nichols, 1999). The cytoskeletal protein, glial
ﬁbrillary acidic protein (GFAP) is usually responsible formodulat-
ing astrocyte shape and motility (Laping et al., 1994). Many of the
effects of neurosteroids on the expression and synthesis of GFAP
are due to their active metabolites. For instance, the gene expres-
sion of GFAP in culture of astrocytes is inhibited by ALLO and
stimulated by DHP, suggesting that different intracellular signal-
ing pathways are likely to be involved in astrocytes proliferation
(Melcangi et al., 1996). Nevertheless, it has been proposed that
the ALLO’s effects on astrocytes are mediated by the activation of
GABA-A receptors,whose subunits are widely distributed in astro-
cytes (Bovolin et al., 1992; Hosli et al., 1997; Israel et al., 2003).
The effects of neuroactive steroids have also been evaluated on
ammonia-induced astrocyte swelling in culture, a phenomena that
occurs early after some acute CNS pathologies such as ischemia
and traumatic brain injury. Bender and Norenberg (1998) showed
that nanomolar concentration of ALLO diminishes the astrocyte
swelling, likely via a GABA-A mechanism. These observations
might be very useful for the development of new therapeutic
approaches to treat the acute hyperammonemic syndromes and
other associated pathological conditions (Bender and Norenberg,
1998).
Allopregnanolone seems to be also involved in the feedback
mechanisms regulating the gonadal axis, and in particular the
neuroendocrine function of the luteinizing-hormone-releasing
hormone (LHRH). Herbison and collaborators provide the ﬁrst
Table 1 | Distribution of major classic and non-classic receptors for neurosteroids in astrocytes.
Classic intracellular receptors Non-classic membrane receptors
PR ER AR GABA-A NMDA mER mPR
Rat glial
culture
(Jung-Testas
et al., 1992)
Pig brain areas
(Langub and
Watson, 1992)
Primate
prefrontal cortex
(Finley and
Kritzer, 1999)
Mouse corpus callosum
(Berger et al., 1992)
Rat celebral cortex (Conti et al.,
1996), spinal cord slice (Ziak
et al., 1998), and injured rat
hippocampus (Krebs et al., 2003)
Rat glial
culture (Kuo
et al., 2011)
Rat spinal
cord (Labom-
barda et al.,
2011)
Rat brain
(Azcoitia et al.,
1999; Cardona-
Gomez et al.,
2000; Milner
et al., 2001)
Rat glial culture
(Jung-Testas
et al., 1992)
Rat hypothalamus (Israel
et al., 2003), hippocampus
(Macvicar et al., 1989; Fraser
et al., 1995; Kang et al., 1998)
spinal cord (Chvatal et al.,
1995; Pastor et al., 1995),
optic nerve astrocytes (Butt
and Jennings, 1994)
Human celebral cortex (Conti
et al., 1999)
Rat glial
culture
(Jung-Testas
et al., 1992;
Santagati
et al., 1994)
Rat glial culture (Kettenmann
et al., 1987; Backus et al.,
1988; Bormann, 1988;
Rosewater and Sontheimer,
1994; Hosli et al., 1997;
Matsutani andYamamoto,
1997)
Mouse cortex (Lalo et al., 2006)
and neocortex (Schipke et al.,
2001)
Human brain and human glial
culture (Lee et al., 2011a,b)
Human glial culture (Lee et al.,
2011a,b)
www.frontiersin.org December 2011 | Volume 2 | Article 103 | 3
Faroni and Magnaghi Allopregnanolone effects in glia
Table 2 | Distribution of major classic and non-classic receptors for neurosteroids in oligodendrocytes.
Classic intracellular receptors Non-classic membrane receptors
PR ER AR GABA-A NMDA mER mPR
Rat glial
culture
(Jung-
Testas
et al., 1992)
Rat glial
culture
(Jung-Testas
et al., 1992;
Santagati
et al., 1994)
Primate
prefrontal
cortex (Finley
and Kritzer,
1999)
Mouse corpus callosum (Berger
et al., 1992)
Rat spinal cord slice (Ziak et al.,
1998), cerebellum and corpus
callosum slices (Karadottir et al.,
2005), and optic nerve (Salter and
Fern, 2005; Micu et al., 2006)
– Rat spinal
cord
(Labom-
barda et al.,
2011)
Rat glial
culture
(Jung-Testas
et al., 1992)
Rat spinal cord (Pastor et al., 1995)
and optic nerve (Borges et al., 1995)
Rat glial culture (Wang et al., 1996)
Mouse glial culture (Gilbert et al.,
1984a; Kettenmann et al., 1984;
Hoppe and Kettenmann, 1989)
Culture of mouse (Von Blankenfeld
et al., 1991; Kirchhoff and
Kettenmann, 1992) and rat
(Belachew et al., 1998;Williamson
et al., 1998) precursor cells.
Table 3 | Distribution of major classic and non-classic receptors for neurosteroids in Schwann cells.
Classic intracellular receptors Non-classic membrane receptors
PR ER AR GABA-A NMDA mER mPR
Rat SC in culture (Jung-Testas et al.,
1996a; Jung-Testas and Baulieu, 1998;
Thi et al., 1998; Magnaghi et al., 1999)
Rat SC in culture
(Jung-Testas and
Baulieu, 1998)
Rat SC in culture
(Magnaghi et al., 1999)
Rat SC in culture
(Melcangi et al., 1999a;
Magnaghi et al., 2006)
Guinea pig SC in
culture (Fink
et al., 1999)
– –
Rat sciatic nerve (Magnaghi et al.,
2001)
Rat sciatic nerve
(Melcangi et al., 1999a;
Magnaghi et al., 2006)
Giant squid SC
(Evans et al.,
1991, 1992)
evidence for a direct action of ALLO on postnatal LHRH neu-
rons, suggesting a new mechanism by which ﬂuctuating P levels
may inﬂuence the secretory activity of these neurons in the female
hypothalamus (Sim et al., 2001). At the cellular level, the increased
ALLO concentration, typical of late pregnancy, has important
physiological actions in repressing the electrical activity of speciﬁc
magnocellular oxytocin neurons in the hypothalamus. Moreover,
the fall inALLOconcentration prior to parturition equally impacts
GABA-A receptor signaling in oxytocin neurons, as well as in the
hippocampus and frontal cortex neurons, suggesting that ALLO’s
concentration changes during pregnancy are likely to exert a pow-
erful regulatory inﬂuence upon neurotransmission in a variety of
brain networks (Herbison, 2001).
However, paracrine mechanisms involving astrocyte cells may
also be at the base of positive or negative feedback signals regu-
lating the reproductive axis. Indeed, growth factors such as trans-
forming growth factor α (TGFα), transforming growth factor β1
(TGFβ1) and β2 (TGFβ2), as well as basic ﬁbroblast growth factor
(bFGF) and insulin-like growth factor-I (IGF-I) are released by
astrocytes and participate in the control of LHRH release (Mel-
cangi et al., 1997; Ojeda and Ma, 1999). ALLO stimulates TGFβ1
gene expression in hypothalamic astrocytes, nevertheless also P
and DHP proved able to exert an identical effect, suggesting that
ALLO’s action may imply an indirect mechanismmediated via PR
(Melcangi et al., 2001a).
ALLO’s EFFECT ON OLIGODENDROCYTE
In mature oligodendrocytes (the cells responsible for forming the
central myelin) the progestagens neurosteroids regulate the gene
expression of some important proteins, such as the myelin basic
protein (MBP) and the 2′-3′-cyclic nucleotide-3-phospodiesterase
(CNPase; Verdi and Campagnoni, 1990; Jung-Testas et al., 1996b).
The age-associated decline in MBP expression levels in 22- to 24-
month-oldmale rats, for instance,was reversed byALLOandDHP,
still indicating a PR-mediated genomic mechanism (Ibanez et al.,
2003). The progestagens involvement on MBP expression regu-
lation in oligodentrocytes was demonstrated also in organotypic
slice cultures of 7-day-old rat and mouse cerebellum (Ghoumari
et al., 2003). This effect likely involves classic PR, since it was
mimicked with the selective PR agonist R5020 and blocked with
the PR antagonist mifepristone (Ghoumari et al., 2003). However,
ALLO signiﬁcantly stimulates MBP expression in 7-day-old rat
andmouse cerebellum cultures, and this effect seemed to bemedi-
ated via GABA-A receptor activation. In accordance, the GABA-A
antagonist bicuculline counteracts the ALLO stimulatory effect,
conﬁrming a GABA-A-mediated mechanism (Ghoumari et al.,
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2003). It is important to underline that some GABA-A receptor
subunits are expressed in oligodendrocytes (Gilbert et al., 1984b)
and in oligodendrocyte progenitor cells (Kettenmann et al., 1984;
Kirchhoff and Kettenmann, 1992). Gago et al. (2004) observed
that the neuroactive steroids and GABA signaling are responsible
for the autocrine/paracrine loops controlling neuronal progen-
itors proliferation and differentiation. The neuronal progenitor
polysialylated-neural cell adhesion molecule positive cells (PSA-
NCAM+), indeed, possess several GABA-A receptor subunits
(Nguyen et al., 2003; Gago et al., 2004), like the α1-5, β2, β3, and
γ2 isoforms (Gago et al., 2004). Interestingly, GABA increased in
a dose dependent manner the proliferation of these cells and the
effect was bicuculline sensitive, suggesting a GABA-A-mediated
mechanism. The effect on the PSA-NCAM+ proliferation was
also mimicked by nanomolar concentration of ALLO. Moreover,
P via its conversion in ALLO, proved able to stimulate the early
PSA-NCAM+ progenitor proliferation (Gago et al., 2004).
Collectively, these ﬁndings suggest a pivotal role of ALLO and
GABA in the development and maturation of oligodendrocytes
(Ben-Ari, 2002; Gago et al., 2004).
ALLO’s EFFECT ON MICROGLIA
Steroids exert anti-inﬂammatory actions in the peripheral tissues
as well as in the brain, where they act mainly on microglial cells.
In this regard, some efforts were addressed to study the neuro-
protective role of estrogens and progesterone on microglial cells
(Stone et al., 1997; Vegeto et al., 1999, 2001; Drew and Chavis,
2000; Bruce-Keller et al., 2001). In parallel, several line of evi-
dence showed that ALLO plays a neuroprotective role following
different brain injury conditions, such as ischemic damage (Kelley
et al., 2011), PTX-induced seizures (Singh et al., 2010) and oxygen-
glucose deprivation (Ardeshiri et al., 2006). The concentrations of
ALLO are also remarkably high in the fetal brain and further rise
in response to acute hypoxia, representing an endogenous protec-
tive mechanism in the developing brain (Hirst et al., 2006). These
effects might be generally ascribed to ALLO’s regulation of anti-
inﬂammatory cytokines and endogenous antioxidants, although
only few evidences rely on the direct effect of ALLO on microglial
cells. For instance, the endogenous concentration of ALLO in
the brain is increased concomitantly to the lipopolysaccharides-
induced tumor necrosis factor α (TNFα) production, which in
turn inhibits TNFα levels (Ghezzi et al., 2000). ALLO also protects
against apoptotic cell death in an in vivo model of rat prefrontal
cortex injury, even if this effects were not totally referred to a
microglial cell disregulation (Djebaili et al., 2005).
ALLO’s EFFECT ON SC
Over the last few decades a large body of evidence has accumu-
lated from investigations into the potential effects that neuros-
teroids exert on SC, which are the cells ensheathing axons and
forming the myelin in the PNS (Jessen and Mirsky, 1997). The
ﬁrst studies started when Baulieu and colleagues focused their
attention on neurosteroid biosynthesis, analyzing primarily the
peripheral nerves, such as the sciatic nerve, and the SC (Jung-
Testas et al., 1993). The progestagens, P and its 5α-derivatives
(DHP and ALLO) have been studied in vivo, demonstrating that
they are able to modulate several biochemical and morphological
parameters of the PNS (Melcangi et al., 2000c; Magnaghi et al.,
2001). For instance, progestagens stimulated the expression of spe-
ciﬁc peripheral myelin proteins, such as the myelin protein zero
(P0) and the peripheral myelin protein 22 (PMP22), in the sciatic
nerve of young and old male rats (Melcangi et al., 1998, 1999a,
2000c; Magnaghi et al., 2001). Moreover, they reduced myelin
abnormalities and ﬁbers loss in aged sciatic nerve (Azcoitia et al.,
2003), promoting re-myelination after cryolesion (Koenig et al.,
1995), transection (Melcangi et al., 2000a), or crush injury (Roglio
et al., 2008). Mifepristone (RU38486), a classic PR antagonist, was
recently studied because of its ability in decreasing the PMP22
overexpression in a rat model of peripheral inherited neuropa-
thy (i.e., the Charcot Marie Tooth type 1A, CMT1A; Sereda et al.,
2003). These results lead to the conclusion that PR likely partic-
ipates in the control of speciﬁc peripheral myelin proteins, such
as P0 and PMP22 (Magnaghi et al., 2001). Nevertheless, in vitro
studies showed that ALLO, besides the ability of increasing P0
mRNA levels, is the main neurosteroid able to stimulate the lev-
els of PMP22 mRNA and protein (Melcangi et al., 1999a, 2000b;
Magnaghi et al., 2001).
Allopregnanolone is a potent modulator of GABA-A receptor,
which subunits arewidely distributed in SC (Melcangi et al., 1999a;
Magnaghi et al., 2006). SC in culture, indeed, express the messen-
gers for several GABA-A receptor subunits, that is α 2 and 3, β 1,
2, and 3 (Melcangi et al., 1999a; Magnaghi et al., 2006).
Therefore, to investigate if the effect of ALLOonPMP22 expres-
sion was mediated by interaction with GABA-A receptors, ALLO’s
stimulation was mimicked with speciﬁc GABA-A ligands. Bicu-
culline, a speciﬁcGABA-A antagonist, abolishes the effect of ALLO
on PMP22 expression levels, whereas muscimol (a speciﬁc GABA-
A agonist) mimics ALLO’s action (Magnaghi et al., 2001, 2006),
conﬁrming the hypothesis that the expression of PMP22 in SC is
under the control of GABA-A receptors. However, ALLO’s action
via the GABAergic system in SC is even more complex, because
it also involves the GABA-B receptor and the endogenous GABA
neurotransmitter (see Figure 1 for details).
Recent observations obtained by reverse transcriptase-
polymerase chain reaction, western blot and immunohistochem-
istry analyses conﬁrmed the presence of GABA-B receptor sub-
units (1a, 1b, and 2) in SC, where the functional receptor was
proved to be negatively coupled to the adenylate cyclase system
(Magnaghi et al., 2004). The activation of the GABA-B receptor
in SC inﬂuences cell proliferation, as demonstrated with baclofen
treatment that counteracted the forskolin-induced SC prolifer-
ation at 5 days in vitro (Magnaghi et al., 2004); at the same
time point also the percentage of BrdUrd immunopositive SC
was reduced (Magnaghi et al., 2004). Since the activation of
the adenylate cyclase system potentially regulates SC prolifera-
tion (Lee et al., 1999; Mirsky and Jessen, 1999), we speculated
that GABA-B-induced decrease in cAMP levels may affect the
cell proliferation (Magnaghi et al., 2004). Notably, changes in
cAMP levels in SC may also inﬂuence the expression of speciﬁc
myelin proteins (Suter et al., 1994; Scherer et al., 1995; Lee et al.,
1999). In agreement, GABA-B activation decreases the expression
of some importantmyelin proteins, like P0,PMP22 as well as other
proteins, like connexin 32 and the myelin associated glycoprotein
(MAG; Magnaghi et al., 2004).
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Investigating the putative effects of neurosteroids on GABA-
B receptor subunits expression in the SC in vitro, it was also
shown that ALLO controls the expression of different GABA-B
receptor subunits (Magnaghi et al., 2006). The expression pro-
ﬁle was biphasic; after 4 h of exposure ALLO produces a robust
stimulation of the mRNA of all three subunits, -1a, -1b, and -
2, while at 24 h of exposure ALLO decreased the expression of
-1b and -2 subunits (Magnaghi et al., 2006). Since ALLO’s effect
on GABA-B receptor expression was mimicked by muscimol and
GABA, it was hypothesized that ALLO regulates GABA-B recep-
tor via a GABA-A-mediated mechanism (Magnaghi et al., 2006;
Magnaghi, 2007). The intracellular pathways downstream of this
interaction is rather complicated and presently not completely
identiﬁed, however a possible hypothesis is proposed below. After
24 h of exposure, P and DHP give rise to a GABA-B receptor mod-
ulation similar to that induced by ALLO. The longer time required
leads to the hypothesis that P and DHP effects are due to their
5α-R-3α-HSD mediated conversion into ALLO (Magnaghi et al.,
2006; Magnaghi, 2007). Therefore, GABA-B subunits expression
may be differently inﬂuenced, mainly by ALLO via a GABA-A-
mediated mechanism, but also by its precursors P and/or DHP
after 5α-R-3α-HSD conversion into ALLO.
Most of the effects exerted by ALLO in SC were achieved at
nanomolar concentration, involving an allosteric interaction that
necessarily entails the presence of the endogenous ligand GABA.
To make the issue even more puzzling, the presence of GABA and
its syntheticmachinerywas thus demonstrated in SC. In particular
the glutamic acid decarboxylase of 67 kDa (GAD67), a key enzyme
for GABA synthesis, was shown to be expressed in SC. Acting in a
way that resemble an autocrine loop,ALLO (10 nM) increased the
levels of GAD67 in SC, thus stimulating GABA synthesis and pro-
viding the natural ligand for GABA-A receptor (Magnaghi et al.,
2010).
Finally, in line with this hypothesis, it was recently demon-
strated that SC in vitro possess a functionally active glutamate
uptake system able to provide glutamate as a precursor for the
synthesis of GABA (Perego et al., 2011). Indeed, it was ﬁrst demon-
strated that SC express the excitatory amino acid transporter 1
(EAAC1) in the plasma membrane and in intracellular vesicular
compartments of the endocytic recycling pathway. Interestingly,
EAAC1 activity can be modulated by exposure of SC to ALLO
10 nM. The transporter up-regulation by ALLO was rapid, did
not involve protein neo-synthesis and was prevented by actin
depolymerization. The modulation exerted by ALLO involved
FIGURE 1 | Schematic representation showing ALLO, GABA and its
receptors (GABA-A and GABA-B) acting in the bidirectional cross-talk
between neurons and SC.We propose the following hypothesis on the
functional role of the GABAergic system in SC. GABA, coming from the
neuronal compartment or produced by the SC (Magnaghi et al., 2010),
may affect the paracrine cross-talk between these cells. The extracellular
GABA might interact with the GABA-B receptor on the SC surface,
decreasing their proliferation (Magnaghi et al., 2004). This challenge then
diminishes the cAMP levels, reducing the myelin proteins expression
(Magnaghi et al., 2004) and prompts the SC to start differentiation. The
neurosteroid ALLO, which is produced by SC (Baulieu and Schumacher,
1997; Melcangi et al., 1999b) allosterically activates the GABA-A receptor
on the SC surface (Magnaghi et al., 2006). This modulates the expression
and the responsiveness of the GABA-B receptor (Magnaghi et al., 2006,
2010), and in turn its desensitization. Contemporarily, ALLO stimulates the
SC proliferation (Perego et al., 2011), inducing other genomic effects such
as the increase of myelin proteins (Melcangi et al., 1999a; Magnaghi
et al., 2001), and the rising of GAD and GABA levels (Magnaghi et al.,
2010). The last effect, being a sort of autocrine mechanism, involving
enhanced cAMP levels and the PK-A pathway. Collectively, these ﬁndings
suggest that an autocrine mechanism involving ALLO and GABA is
particularly relevant for the control of SC proliferation/differentiation, and
may be considered the result of a balanced activation of GABA-A or
GABA-B receptors on SC.
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GABA-A receptor and PK-C activation, promoting the exocyto-
sis of the EAAC1 transporter from intracellular stores to the SC
membrane (in actin-rich cell tips), and modifying the morphol-
ogy of SCprocesses. The evidence that EAAC1 transporter controls
the ALLO-mediated effects on SC proliferation was also provided
(Perego et al., 2011).
DOWNSTREAM MECHANISM FOLLOWING ALLO’s
ACTIVATION OF GABA-A RECEPTOR: IS THE PUZZLE
UNPUZZLED?
Several attempts in the literature tried to explain the intracellular
molecular mechanism downstream to ALLO’s allosteric activa-
tion of GABA-A receptor, in neurons as well as in central and/or
peripheral glial cells. For instance, in the developing rat cor-
tex, GABA-A receptor activation leads to the opening of L-type
voltage-gated calcium channels, resulting in an increase of cal-
cium inﬂux,which in turn leads to phosphorylation and activation
of the transcription factor cAMP response element-binding pro-
tein (CREB) and ﬁnally controls neuronal nitric oxide synthase
and brain derived neurotrophic factor expression (Mantelas et al.,
2003). However, it should be underlined that the presence of
endogenous GABA is the ﬁrst precondition for ALLO’s allosteric
action. The synthesis of GABA was previously shown in astrocytes
and oligodendrocytes, and very recently also in SC (Magnaghi
et al., 2010).
Therefore, the interaction among the neurosteroid ALLO,
GABA-A, andGABA-B receptors is relevant, at least in the PNS, for
the bidirectional cross-talk between neurons and SC (Figure 1).
GABA, coming from the neuronal compartment, or produced
by SC (Magnaghi et al., 2010) may affect the paracrine inter-
play between these cells. In fact, data obtained with the speciﬁc
GABA-B ligand baclofen suggest that extracellular GABA might
interact with GABA-B receptors on SC, decreasing their pro-
liferation, the cAMP levels and the myelin proteins expression.
This effect promotes SC differentiation. ALLO produced by SC
(Baulieu and Schumacher, 1997; Melcangi et al., 1999b) via a
direct action on GABA-A receptor modulates the GABA-B recep-
tor expression, distribution and responsiveness, and in turn its
desensitization. Contemporarily,ALLOmay increase somemyelin
proteins expression in SC. Muscimol mimicked this effect on SC,
further supporting that GABA-A might also participate in the
control of the SC proliferation/differentiation (Figure 1).
However, the nature of the signaling pathways downstream
to the ALLO’s allosteric modulation of GABA-A receptor is still
debated. We suggest an involvement of the protein kinase A (PK-
A) pathway, which through enhanced cAMP levels and CREB
phosphorylation, modulates the allosteric action of ALLO at the
GABA-A receptor (Magnaghi et al., 2010). However, other protein
kinases should be also considered. In fact, the allosteric ALLO’s
modulation of GABA-A receptor, regulating glutamate uptake via
EAAC1 transporter, is dependent by a PK-C activation, as con-
ﬁrmed by the very recent analysis of the pharmacological proﬁle
(Perego et al., 2011). Whether this relatively rapid ALLO’s action
on GABA-A receptor in glial cells may lead to ion channels open-
ing, as occur in neuronal cells, should not be totally excluded and
deserves further investigation.
CONCLUSION
In this review we focused our attention on the putative effects
of ALLO on the glial cells of the CNS and PNS, with a partic-
ular emphasis on ALLO’s regulation of glial physiology in nor-
mal and/or pathological conditions. The mechanism by which
ALLO exerts these controls is part of the “non-genomic” action
of steroids, involving the rapid modulation of neurotransmitter
receptors such as the GABA receptors. However, ALLO’s action
on GABA-A receptor somehow involves downstream “genomic”
mechanisms that are yet to be completely elucidated. In SC these
intracellular mechanisms imply the activation of PK-A and PK-C
signaling pathways, which in turn may determine the physio-
logic control of SC proliferation/differentiation. Nevertheless, an
involvement of other intracellular pathways, for instance ion cal-
ciumchannels, as observed in rat neuroprogenitor cells andhuman
neural stemcells (Wang et al.,2005), shouldbe further investigated.
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